

**RESEARCH**
**BOB Economics Research | Weekly Wrap**

Over to RBI now

**Automobiles**

Jan'20 Auto Sales – PVs ahead of 2W and CVs

**SUMMARY**
**India Economics: Weekly Wrap**

Global yields fell led by US over concerns of economic impact of coronavirus. US consumer confidence remains buoyant. Equity markets and oil prices too fell in the week. Both US Fed and BoE started the year by keeping rates on hold. India's FM presented a counter cyclical budget to stem an investment and consumption led slowdown. Fiscal deficit was expanded to 3.8% of GDP in FY20 and 3.5% in FY21. Gross borrowing was unchanged in FY20 and increased by only Rs700bn in FY21 which cheered bond markets.

[Click here for the full report.](#)

**Automobiles**

Jan'20 volume trends were mixed across segments and players based on stock levels and differing timelines for BS-VI production ramp-up. PV growth stayed negative but MSIL and MM posted above-expected volumes. 2W wholesale volumes were weak as system inventory continued to trend higher. MHCVs saw another month of sharp wholesale volume cuts on BS-IV inventory correction. Restocking is likely to pick up towards the tail end of Q4FY20. We continue to prefer PVs over 2W and CVs; MSIL and EIM are top picks and AL is a SELL.

[Click here for the full report.](#)

**TOP PICKS**
**LARGE-CAP IDEAS**

Company	Rating	Target
<a href="#">Bajaj Finance</a>	Buy	5,200
<a href="#">Cipla</a>	Buy	570
<a href="#">Eicher Motors</a>	Buy	25,000
<a href="#">Petronet LNG</a>	Buy	400
<a href="#">Reliance Industries</a>	Buy	1,860

**MID-CAP IDEAS**

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	2,290
<a href="#">Future Supply</a>	Buy	680
<a href="#">Greenply Industries</a>	Buy	210
<a href="#">Laurus Labs</a>	Buy	510
<a href="#">Ashok Leyland</a>	Sell	68

Source: BOBCAPS Research

**DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.51	(8bps)	(41bps)	(118bps)
India 10Y yield (%)	6.60	4bps	5bps	(77bps)
USD/INR	71.35	0.2	0	(0.1)
Brent Crude (US\$/bbl)	58.16	(0.2)	(11.9)	(7.3)
Dow	28,256	(2.1)	(1.0)	12.7
Shanghai	2,977	(2.8)	(2.4)	13.7
Sensex	39,736	(2.4)	(3.7)	9.0
India FII (US\$ mn)	30 Jan	MTD	CYTD	FYTD
FII-D	43.2	(1,553.5)	(1,553.5)	1,390.6
FII-E	87.6	1,984.5	1,984.5	9,373.7

Source: Bank of Baroda Economics Research

**BOBCAPS Research**

research@bobcaps.in



## WEEKLY WRAP

03 February 2020

**Over to RBI now**

**Global yields fell led by US over concerns of economic impact of coronavirus. US consumer confidence remains buoyant. Equity markets and oil prices too fell in the week. Both US Fed and BoE started the year by keeping rates on hold. India's FM presented a counter cyclical budget to stem an investment and consumption led slowdown. Fiscal deficit was expanded to 3.8% of GDP in FY20 and 3.5% in FY21. Gross borrowing was unchanged in FY20 and increased by only Rs700bn in FY21 which cheered bond markets.**

Sameer Narang | Jahnavi

chief.economist@bankofbaroda.com

**Markets**

- **Bonds:** Except India, global yields closed lower as concerns over spread of coronavirus escalated. US 10Y yield fell the most by 18bps (1.5%) in the week. Oil prices fell by (-) 4.2% to US\$ 58/bbl. India's 10Y yield rose by 2bps (6.6%). However it opened 10bps lower today as gross borrowing for FY20 was unchanged at Rs 7.1tn and increased by only Rs 700bn in FY21. System liquidity surplus rose to Rs 3.4tn as on 31 Jan 2020 vs Rs 2.8tn in the previous week.
- **Currency:** Global currencies closed mixed this week as fears over the spread of coronavirus outbreak in China and its economic impact remained in focus. AUD fell by (-) 2% and CNY fell by (-) 0.9%. DXY also fell by (-) 0.5% in the week as US GDP grew at its weakest pace in 3-years in CY19. GBP rose by 1% after BoE kept its policy rate steady. INR closed stable even as oil prices fell. FII outflows were US\$ 361mn.
- **Equity:** Global indices ended lower this week as concerns over spread of coronavirus continued to weigh-in. European indices ended in red led by lower than expected GDP estimate for Q4CY19 and dovish tone of BoE as it trimmed growth forecast for CY20. Amongst other indices, Sensex (-4.5%) had the biggest fall as the budget failed to cheer investors. Chinese markets were closed and opened today (-) 9%.
- **Upcoming key events:** In the current week, markets will await manufacturing and services PMI of Eurozone, China and US. Apart from this, RBI, RBA, Philippines and BoT policy is also scheduled. Additionally, China's and Germany's exports data is also awaited.



## AUTOMOBILES

03 February 2020

### Jan'20 Auto Sales – PVs ahead of 2W and CVs

Jan'20 volume trends were mixed across segments and players based on stock levels and differing timelines for BS-VI production ramp-up. PV growth stayed negative but MSIL and MM posted above-expected volumes. 2W wholesale volumes were weak as system inventory continued to trend higher. MHCVs saw another month of sharp wholesale volume cuts on BS-IV inventory correction. Restocking is likely to pick up towards the tail end of Q4FY20. We continue to prefer PVs over 2W and CVs; MSIL and EIM are top picks and AL is a SELL.

Navin Matta | Nishant Chowhan, CFA  
 research@bobcaps.in

**Passenger vehicles slightly ahead of estimates:** We estimate aggregate PV sales declined 5-7% YoY in Jan'20. Maruti Suzuki's (MSIL) domestic PV sales grew 2% YoY, while exports were up 1%. Its SUV volumes declined a sharp 27% YoY given destocking ahead of the 'Brezza' petrol launch in Feb'20. M&M's (MM) PV sales declined by 17% YoY, whereas Tata Motors (TTMT) saw a 35% YoY drop to 13,894 units. Per the company, 'Altroz' has garnered a good response and has a strong order backlog. Among other major PV OEMs, domestic volumes for Hyundai/Toyota/Honda were down 8%/48%/71% YoY.

**Two-wheelers remain in slow lane:** 2W wholesale volumes remained under pressure given continued BS-IV inventory rationalisation. Hero MotoCorp's (HMCL) sales fell 14% YoY led by a sharp drop in scooter volumes (-87% YoY), while the decline in motorcycle volumes was moderate at 6% YoY. Royal Enfield sales slipped 13% YoY. TVS Motors' (TVSL) total sales fell 17% YoY led by a domestic decline of 9% while exports grew 34% on a low base. Weak domestic volumes were partially on account of early transition to BS-VI.

**Commercial vehicles see continued weakness:** MHCV volumes are still to reflect any volume uptick from pre-buying. TTMT's domestic CV sales dropped 16% YoY as MHCV sales plunged 41% due to the weak macro climate. Ashok Leyland's (AL) domestic sales nosedived 41% YoY due to a 49% fall in MHCVs. VECV domestic volumes slipped 6% YoY with a 15% drop in domestic heavy truck sales.

**Tractor sales recover:** MM's tractors sales rose 4% YoY while sales for competitor Escorts (ESC) grew 1%. Good 'rabi' output and government's increased focus on the rural sector would drive positive momentum for tractors.

### KEY RECOMMENDATIONS

Ticker	Price	Target	Rating
AL IN	78	68	SELL
BJAUT IN	3,282	3,560	ADD
EIM IN	20,000	25,000	BUY
HMCL IN	2,392	2,575	REDUCE
MM IN	560	625	ADD
MSIL IN	7,010	8,825	BUY
TTMT IN	164	212	ADD
TVSL IN	470	465	REDUCE

Price & Target in Rupees

### SALES SNAPSHOT

Ticker	Volume	YoY (%)	MoM (%)
AL IN	11,850	(40.0)	6.1
EIM IN*	69,064	(12.1)	24.6
HMCL IN	501,622	(13.9)	18.1
MM IN	75,662	(2.9)	32.2
MSIL IN	154,123	1.6	15.6
TVSL IN	234,920	(16.9)	1.4
TTMT IN	47,932	(17.6)	2.1

Source: Company | \*RE & VECV combined

[Click here for our Sector Report](#)  
 'Mixed signals – prefer PVs, 2Ws'



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 31 January 2020, out of 85 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 8 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.